Description

The traditional model for drug development begins with publicly-funded science based in academic or government laboratories before private investors and for-profit pharmaceutical manufacturers become involved with their substantial expertise and resources. This for-profit drug development model has been criticized for leaving certain public health issues unaddressed, particularly diseases prevalent in low-resource settings. What is the viability of other alternatives for funding drug discovery and development?

Panelists

• Rachel Cohen, Regional Executive Director, Drugs for Neglected Diseases Initiative (DNDi) North America
• Sergio Sismondo, Professor of Philosophy and Sociology, Queen’s University
• Ameet Sarpatwari, Assistant Professor of Medicine, Harvard Medical School and Assistant Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham & Women’s Hospital

The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations.

They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women’s Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.